Connection

YONGCHENG SONG to Animals

This is a "connection" page, showing publications YONGCHENG SONG has written about Animals.
Connection Strength

0.387
  1. Synthesis, Structure-Activity Relationships, and Antitumor Activities of Quinoxiline-Containing Inhibitors of the Protein-Protein Interactions between Transcription Coactivator AF9/ENL and DOT1L/AF4. J Med Chem. 2025 Sep 25; 68(18):19396-19414.
    View in: PubMed
    Score: 0.053
  2. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. J Hematol Oncol. 2022 04 08; 15(1):41.
    View in: PubMed
    Score: 0.042
  3. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth. Theranostics. 2021; 11(17):8172-8184.
    View in: PubMed
    Score: 0.040
  4. Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. J Med Chem. 2021 03 11; 64(5):2777-2800.
    View in: PubMed
    Score: 0.039
  5. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020 05 13; 13(1):50.
    View in: PubMed
    Score: 0.037
  6. Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics. 2018; 8(8):2189-2201.
    View in: PubMed
    Score: 0.032
  7. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016 Mar 12; 9:24.
    View in: PubMed
    Score: 0.028
  8. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget. 2014 Nov 15; 5(21):10665-77.
    View in: PubMed
    Score: 0.025
  9. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L. J Med Chem. 2013 Nov 27; 56(22):8972-83.
    View in: PubMed
    Score: 0.023
  10. A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. Proc Natl Acad Sci U S A. 2023 10 31; 120(44):e2307793120.
    View in: PubMed
    Score: 0.012
  11. Norovirus Protease Structure and Antivirals Development. Viruses. 2021 10 14; 13(10).
    View in: PubMed
    Score: 0.010
  12. A steroid receptor coactivator stimulator (MCB-613) attenuates adverse remodeling after myocardial infarction. Proc Natl Acad Sci U S A. 2020 12 08; 117(49):31353-31364.
    View in: PubMed
    Score: 0.010
  13. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 08 18; 128(7):971-81.
    View in: PubMed
    Score: 0.007
  14. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 03; 7(18):26307-30.
    View in: PubMed
    Score: 0.007
  15. Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy. Nat Commun. 2014 Nov 17; 5:5476.
    View in: PubMed
    Score: 0.006
  16. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. J Med Chem. 2014 Oct 23; 57(20):8307-18.
    View in: PubMed
    Score: 0.006
  17. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
    View in: PubMed
    Score: 0.006
  18. Biochemical control of CARM1 enzymatic activity by phosphorylation. J Biol Chem. 2009 Dec 25; 284(52):36167-36174.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.